Index · Artikel · Roche in $5.7 billion bid for gene decoder Illumina

Roche in $5.7 billion bid for gene decoder Illumina

2012-01-25 3
résuméZURICH/LONDON Swiss drugmaker Roche Holding AG ROG.VX has offered $5.7 billion in cash in a hostile bid to take over Illumina Inc (ILMN.O), and investors are already betting that the U.S. gene sequencing company will command a significantly higher pr

Roche in $5.7 billion bid for gene decoder Illumina

ZURICH/LONDON Swiss drugmaker Roche Holding AG ROG.VX has offered $5.7 billion in cash in a hostile bid to take over Illumina Inc (ILMN.O), and investors are already betting that the U.S. gene sequencing company will command a significantly higher price.

Gene sequencing is central to the future of medicine as it allows researchers and physicians to better predict which patients are likely to respond to a particular drug.

Illumina is a market leader in the sequencing machines that give details on an individual's genome. Their products would nicely complement Roche's world-leading position in cancer drugs, which are increasingly being developed with companion diagnostic tests to determine the best fit with patients.

Illumina's value to Roche was evident in a 45 percent jump for its shares on Wednesday, putting them more than $10 above Roche's offer of $44.50 per share.

"The market is clearly pricing in here a very high probability of a deal being done at $55 to $60 (per share)," said Deutsche Bank analyst Ross Muken.

"The real question becomes whether or not we see another bidder, and that will determine how aggressive Roche needs to become in terms of follow-up bids," Muken said.

Roche Chief Executive Severin Schwan said the company had no intention of raising its offer for San Diego-based Illumina, which was founded in 1998 and employs just over 2,000 people.

But Roche has taken a similar tack in previous acquisitions only to come back with higher bids, as was the case in its purchase of Ventana Medical Systems and buyout of Genentech.

"It does feel like it's Roche's initial bid at only about a 15 percent premium (actually 18 percent) to yesterday's close," said Mizuho Securities analyst Peter Lawson, who expects the final price to be in the $60 to $80 per share range. "They kind of play this game of sitting around for a while on the bid."

Pharma industry bankers say Abbott Laboratories (ABT.N), Amgen (AMGN.O), Siemens (SIEGn.DE) and General Electric (GE.N) are all potential interlopers who would look at Illumina's business, but they question whether any would make a competing bid.


With Schwan as its diagnostics chief, Roche in 2008 overcame months-long resistance from test maker Ventana to snap it up for $3.4 billion. It had made an unsolicited, low-end bid, before increasing its original offer by 19 percent.

"When you look at the Ventana situation that gives you somewhat of a window into how they're likely to handle this," said Deutsche Bank's Muken, adding that it will likely take another bidder to drive the price north of $60.

Illumina investors will likely point to the fact that company shares were worth more than $77 as recently as July to argue for a higher bid. The stock has dropped due to uncertainty over academic and government research spending that has hit the entire life sciences sector particularly hard.

The Roche offer equates to about 30 times Illumina's forecast 2012 earnings, and more than a 60 percent premium to its December 21 closing price just before takeover chatter boosted shares.

A deal for Illumina would help Roche's large diagnostic business. It could also boost Illumina's market position as it faces fiercer competition in the genomics space.

"(A deal) will help Roche sustain its leadership position in targeted therapies, which we consider as highly promising," said Bryan Garnier analysts in a research note.

Mizuho's Lawson notes that Illumina is seen as having the dominant technology in the space, "but there are some very interesting technologies coming through on the sequencing side, for instance Life Technology's (LIFE.O) Ion Torrent instrument, that puts things on a new curve."

Earlier this month, Life Tech said it would sell a tabletop machine that can sequence a person's entire genome for just $1,000, turning a research tool into a device that could become commonplace in medical clinics.

Many analysts and scientists believe that sequencing technology, which could lead to discoveries of genetic links to many diseases from autism to cancer, has the potential to revolutionize medicine.


Basel-based Roche, which currently owns a very small number of Illumina shares, said it plans to start a tender offer because Illumina was not willing to negotiate a transaction.

"Roche has made multiple efforts to engage with Illumina in order to reach a negotiated transaction, but Illumina has been unwilling to participate in substantive discussions," it said.

The deal would be Roche's largest since it bought the remaining stake in U.S. biotech Genentech for nearly $47 billion in 2009. It would be financed from available cash and borrowing under its credit facilities, Roche said.

The company also said it would nominate a slate of independent candidates for election to Illumina's board.

"It is our strong preference to enter into a negotiated transaction with Illumina," Schwan said.

Illumina urged shareholders to take no action pending a recommendation from the board.

Capital Research Global Investors, Baillie Gifford & Co, Sands Capital Management, Morgan Stanley Investment Management and Jennison Associates are the five biggest shareholders of Illumina. They collectively own about 44 percent of the company's outstanding shares, according to Thomson Reuters data based on filings.

Roche shares closed down 2.8 percent at 160 Swiss francs, lagging a 1 percent drop in the European healthcare index .SXDP. Shares of Illumina rivals Life Tech and Affymetrix were up more than 3 percent each.

Roche said it has hired Greenhill & Co and Citigroup as financial advisers. Goldman, Sachs & Co and Bank of America Merrill Lynch are acting for Illumina.

(Additional reporting by Sakthi Prasad in Bangalore, Ben Hirschler in London and Bill Berkrot in New York; Editing by Chris Wickham, Mark Potter and Michele Gershberg)


  • Day/
  • Week/
  • Original/
  • Recommand


  • Fibromyalgie - WIE KANN Mucinex KONFLIKT MIT Savellà NEHMEN?

    Ich bemerke, ON DRUGS.COM, dass es eine BEKANNTMACHUNG Meds die in Konflikt mit FIBRO MEDS UND Mucinex ist auf der Liste ----schneiden---- In Antwort auf die Marvell bei 2009-11-18 04.12 Es gibt keine bekannten Wechselwirkungen zwischen Mucinex und S
  • Eating eggs doesn't seem to up diabetes risk

    Eating eggs doesn't seem to up diabetes risk
    NEW YORK (Reuters Health) - An egg a day for breakfast probably won't increase your likelihood of developing type 2 diabetes, according to a new study. In the study, researchers failed to see a significant association between eating eggs occasionally
  • Über Allergie-Tests?

    Ich habe für eine lange Zeit Allergien gekämpft, gehe ich zum Arzt und sie geben mir medicatins Inhalatoren, albuteral, Einzahl, atibiotics, Prednison, meine Fragen, die ich denke, dass ich allergisch auf Katzen bin, und ich habe meine Töchter zwei K
  • Ist Ketoconazol Schaum gut für die Behandlung erythrasma?

    Ich habe seit fast 15 Jahren erythrasma in der Leistengegend hatte. Es flackert, wenn ich zu warm oder verschwitzt bin. Der Pruritus ist in der Nacht schrecklich, was es schwierig macht, um zu schlafen. Wurde unter Erythromycin Pillen 4x / Tag 500mg.
  • Ist pepcid AC wirksam nach dem Ablaufdatum?

    Ich habe eine Schachtel PepcidAC, die nach Ablauf des Verfallsdatum 8 Monate ist. Es ist immer noch verschlossen, und ich wollte wissen, ob es immer noch wirksam sein wird? ----schneiden---- In Antwort auf 2015.08.01 22.47 bis suzanne66 Sobald ein Me
  • Physiotherapie-Übungen für Golferellenbogen

    Physiotherapie-Übungen für Golferellenbogen
    1 Golferellenbogen Übungs-Programm Wenn Sie Golferellenbogen haben, auch als mediale Epikondylitis bekannt sind, können Sie aus dem Hand Dienste eines Physiotherapeuten profitieren. Ihre PT können verschiedene Behandlungen und Modalitäten, wie Iontop
  • Sollte Erwachsene mit Autismus leben in der Stadt oder auf dem Land?

    Sollte Erwachsene mit Autismus leben in der Stadt oder auf dem Land?
    Es gibt einige wunderbare Autismus-orientierte Gemeinden liegt auf Bauernhöfen und auf dem Land. Viele Menschen auf dem Spektrum genießen die in ihnen leben. Aber bedeutet das, dass Erwachsene auf das Spektrum in der Regel besser gestellt sind außerh
  • Ebola-Update: Nur 1 Person hatte Kontakt mit infiziertem Krankenschwester

    Ebola-Update: Nur 1 Person hatte Kontakt mit infiziertem Krankenschwester
    Texas Health Presbyterian Hospital Dallas Credit: Texas Health Resources Nur eine Person Kontakt mit der zweiten Person Ebola in Texas während der Zeit zu entwickeln hatte, als sie ansteckend gewesen sein könnte, Gesundheit Beamte sagte heute (13. Ok
  • Hat jemand eine Knielappenoperation hatte?

    Ich bin ein 35 Jahre alter Mann, dessen eine Vereinigung Betonfertiger und zur Zeit auf einer Wunde vac w / Hauskrankenpflege !! Ich habe starke Schmerzen und kann eine Klappe Operation zu unterziehen! Die Ärzte erklärten, was es mir ist, und ich bin
  • Lebensmittel Shopping für den Sport Eltern

    Lebensmittel Shopping für den Sport Eltern
    Egal, ob Sie eine 80-Pfund-Turner oder eine 250-Pfund-verteidiger, intelligente Lebensmittel einkaufen müssen, ist ein Muss für den Sport Eltern. Sie müssen Lebensmittel, die Ihr Kind den Körper und das Gehirn Kraftstoff, helfen Muskeln erholen und I